Clinical Trial Update: A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

The update confirms a Phase 3 study of BPI-7711 capsules for non-small cell lung cancer by Beta Pharma Shanghai is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BPI-7711 Capsule (BPI-7711)

Snippet

Sponsor: Beta Pharma Shanghai | Conditions: NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING